Skip to main content
. 2013 Apr 17;8(4):e61939. doi: 10.1371/journal.pone.0061939

Figure 7. The knockdown of p38MAPK and reduction of erythroid differentiation decreased K562 cell sensitivity to imatinib.

Figure 7

The cells were transfected with a negative control shRNA (ctrl-shRNA) or a shRNA targeting p38α (p38α-shRNA) for 3 days. (A) The protein level of p38MAPK was analyzed by Western blotting (upper panel). Immunoblots are representative of three experiments, which are presented as the mean ± SEM (lower panel). *, p<0.05 versus control-shRNA. (B) K562 cells were transfected with shRNA plasmids and treated without (control) or with ACM (5 nM). Cells were stained with benzidine to determine hemoglobin synthesis at 72 h. (C) The shRNA-transfected cells were treated with ACM (5 nM) for 3 days and then with 200 nM imatinib for additional 3 days (ACM-IM). Cell viability was analyzed by MTT assay. (D) The same experiments as described above were performed. Apoptotic cells were stained with annexin V-FITC and PI and analyzed by flow cytometry. Values are mean ± SEM from three experiments. *, p<0.05 versus untreated control. #, p<0.05 versus ctrl-shRNA/ACM-IM (C and D).